NASDAQ
Kairos Pharma, Ltd. (KAPA) has a free cash flow growth of 4.43% as of Friday, May 29, 2026. This represents a 88.00% decrease compared to its 12-month average of 36.91%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.